168 related articles for article (PubMed ID: 32940805)
1. The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma.
Ohsugi H; Yoshida T; Ohe C; Ikeda J; Sugi M; Kinoshita H; Tsuta K; Matsuda T
Ann Surg Oncol; 2021 Apr; 28(4):2359-2366. PubMed ID: 32940805
[TBL] [Abstract][Full Text] [Related]
2. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
3. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma.
Blackmur JP; Gaba F; Fernando D; Williams S; O'Donnell M; McNeill A; Stewart GD; Leung S; Laird A
Urol Oncol; 2021 Jul; 39(7):438.e11-438.e21. PubMed ID: 34023196
[TBL] [Abstract][Full Text] [Related]
4. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
5. High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma.
Yang Y; Zhai C; Chang Y; Zhou L; Shi T; Tan C; Xu L; Xu J
Urol Oncol; 2016 May; 34(5):238.e19-26. PubMed ID: 26749463
[TBL] [Abstract][Full Text] [Related]
6. β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
Liu Y; Liu H; Liu W; Zhang W; An H; Xu J
World J Urol; 2015 Nov; 33(11):1791-9. PubMed ID: 25630622
[TBL] [Abstract][Full Text] [Related]
7. Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
Wu Q; Yang L; Liu H; Zhang W; Le X; Xu J
Ann Surg Oncol; 2015 Jul; 22(7):2446-53. PubMed ID: 25391266
[TBL] [Abstract][Full Text] [Related]
8. Predictors of postoperative recurrence in patients with non-metastatic pT3a renal cell carcinoma.
Ohsugi H; Ohe C; Yoshida T; Ikeda J; Sugi M; Kinoshita H; Matsuda T
Int J Urol; 2021 Oct; 28(10):1060-1066. PubMed ID: 34346110
[TBL] [Abstract][Full Text] [Related]
9. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma.
Chang Y; Xu L; Zhou L; Fu Q; Liu Z; Yang Y; Lin Z; Xu J
Oncotarget; 2016 Apr; 7(17):24527-36. PubMed ID: 27016418
[TBL] [Abstract][Full Text] [Related]
11. Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma.
Liu Y; Xu L; Zhu Y; Zhang W; Liu W; Liu H; Xu J
Urol Oncol; 2015 Mar; 33(3):112.e1-8. PubMed ID: 25499921
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma.
Yang L; Wu Q; Xu L; Zhang W; Zhu Y; Liu H; Xu J; Gu J
BMC Cancer; 2015 Feb; 15():67. PubMed ID: 25886010
[TBL] [Abstract][Full Text] [Related]
13. Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma.
Fu H; Liu Y; Xu L; Liu W; Fu Q; Liu H; Zhang W; Xu J
Tumour Biol; 2015 Aug; 36(8):5791-9. PubMed ID: 25716202
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma.
Xia Y; Liu L; Long Q; Bai Q; Wang J; Xu J; Guo J
Urol Oncol; 2016 Jan; 34(1):5.e1-9. PubMed ID: 26411550
[TBL] [Abstract][Full Text] [Related]
16. Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.
Palumbo C; Perri D; Zacchero M; Bondonno G; Martino JD; D'Agate D; Volpe A
Urol Oncol; 2022 Apr; 40(4):167.e1-167.e7. PubMed ID: 35034803
[TBL] [Abstract][Full Text] [Related]
17. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma.
Kroeger N; Lebacle C; Hein J; Rao PN; Nejati R; Wei S; Burchardt M; Drakaki A; Strother M; Kutikov A; Uzzo R; Pantuck AJ
Eur J Cancer; 2022 Jun; 168():68-76. PubMed ID: 35461012
[TBL] [Abstract][Full Text] [Related]
18. p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma.
Zhu Y; Xu L; An H; Liu W; Wang Z; Xu J
Int J Urol; 2015 May; 22(5):447-53. PubMed ID: 25711487
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.
Haddad AQ; Luo JH; Krabbe LM; Darwish O; Gayed B; Youssef R; Kapur P; Rakheja D; Lotan Y; Sagalowsky A; Margulis V
BJU Int; 2017 May; 119(5):741-747. PubMed ID: 28075543
[TBL] [Abstract][Full Text] [Related]
20. High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.
Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Long Q; Xu J; Guo J
Oncotarget; 2016 Sep; 7(39):63661-63668. PubMed ID: 27564117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
